Application 200654

Type
ANDA
Sponsor
APOTEX INC

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ANASTROZOLEANASTROZOLETABLET;ORAL1MGNoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A200654-001ANASTROZOLEANASTROZOLE1MGTABLET / ORAL2012-05-11

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ANASTROZOLEANASTROZOLEBreckenridge Pharmaceutical, Inc.ca9d4aff-ffdf-4a46-ad20-e47e5886a19e2026-07-09Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEPD-Rx Pharmaceuticals, Inc.aabd8f88-2b52-4d43-8dc6-61605988c4dc2026-07-07Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEPD-Rx Pharmaceuticals, Inc.54da5c12-cfaf-7a14-e063-6394a90a36352026-06-22Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEBryant Ranch Prepackf5b53383-0366-4ae2-9aa4-88b56c0bbd072026-06-18Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSASCLEMED USA INC.39df1668-8344-4c42-9bd7-7907bd571f6e2026-06-15Warnings, Adverse reactionsName fallback
ANASTROZOLEANASTROZOLENuCare Pharmaceuticals,Inc.69be1c52-93db-e2c3-e053-2a91aa0af7742026-05-28Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSNuCare Pharmaceuticals, Inc.513e8413-af48-4acc-e063-6294a90a24b42026-05-07Warnings, Adverse reactionsName fallback
ANASTROZOLEANASTROZOLEAvPAK94a46579-0d79-89c7-e053-2995a90a64672026-03-10Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEAsclemed USA, Inc.b964f555-25d2-47ad-8942-f195f062445c2026-02-14Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEAccord Healthcare Inc.03586c40-eb32-45c5-beb7-6762a6b787902026-02-11Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEAvKAREa0c2672b-e07b-4f6c-e053-2a95a90a2e5d2026-01-14Warnings, Adverse reactionsName fallback
ANASTROZOLEANASTROZOLEAvKAREf40b925f-9f43-321d-e053-2a95a90aca8b2026-01-13Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSAvet Pharmaceuticals Incf86d2158-b078-3f74-e053-6394a90aa4b62025-12-29Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSYiling Pharmaceutical, Inc.7b3da447-8e7c-2aaa-e053-2a91aa0a28212025-12-29Warnings, Adverse reactionsName fallback
ANASTROZOLEANASTROZOLENuCare Pharmaceuticals, Inc.362034e9-2830-19a5-e063-6394a90a8dfb2025-12-09Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEChartwell RX, LLCda6ae05c-81e9-492a-a4c9-be3f1f367b592025-12-09Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSProficient Rx LP2df2aa01-1fe7-477c-9a23-699879b0b9182025-09-01Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEAmerican Health Packagingdface914-5135-4136-82f4-75429b496a352025-08-29Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLE TABLETSUpsher-Smith Laboratories, LLC7e0bd2cc-d3cc-403f-a6b6-4597ccb2f6852025-07-09Warnings, Adverse reactionsName fallback
AnastrozoleANASTROZOLEAurobindo Pharma Limited71f053c2-8d0d-41a1-8630-2d797eced7992025-05-19Warnings, Adverse reactionsName fallback

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with anastrozole tablet use compared to tamoxifen use. Consider risks and benefits. ( 5.1 , 6.1 ) Decreases in bone mineral density may occur. Consider bone mineral density monitoring. ( 5.2 , 6.1 ) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.3 , 6.1 ) Embryo-Fetal Toxicity: Anastrozole tablets may cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. ( 5.4 , 8.1 ) 5.1 Ischemic Cardiovascular Events In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with anastrozole tablets in the ATAC trial (17% of patients on anastrozole tablets and 10% of patients on tamoxifen). Consider risk and benefits of anastrozole tablets therapy in patients with pre-existing ischemic heart disease [see Adverse Reactions (6.1) ]. 5.2 Bone Effects Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole tablets had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline. Consider bone mineral density monitoring in patients treated with anastrozole tablets [see Adverse Reactions (6.1) ]. 5.3 Cholesterol During the ATAC trial, more patients receiving anastrozole tablets were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively) [see Adverse Reactions (6.1) ]. 5.4 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, anastrozole tablets can cause fetal harm when administered to a pregnant woman. Anastrozole caused embryo-fetal toxicities in rats at maternal exposure that were 9 times the human clinical exposure, based on area under the curve (AUC). In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 16 times the recommended human dose on a mg/m 2 basis. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during therapy with anastrozole tablets and for...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS Serious adverse reactions with anastrozole tablets occurring in less than 1 in 10,000 patients, are: 1) skin reactions such as lesions, ulcers, or blisters; 2) allergic reactions with swelling of the face, lips, tongue, and/or throat. This may cause difficulty in swallowing and/or breathing; and 3) changes in blood tests of the liver function, including inflammation of the liver with symptoms that may include a general feeling of not being well, with or without jaundice, liver pain or liver swelling [see Adverse Reactions (6.2) ]. Common adverse reactions (occurring with an incidence of ≥10%) in women taking anastrozole tablets included: hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis and lymphedema. In the ATAC trial, the most common reported adverse reaction (>0.1%) leading to discontinuation of therapy for both treatment groups was hot flashes, although there were fewer patients who discontinued therapy as a result of hot flashes in the anastrozole tablets group. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the early breast cancer (ATAC) study, the most common (occurring with an incidence of ≥10%) side effects occurring in women taking anastrozole tablets included: hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema and lymphedema, regardless of causality. ( 6.1 ) In the advanced breast cancer studies, the most common (occurring with an incidence of >10%) side effects occurring in women taking anastrozole tablets included: hot flashes, nausea, asthenia, pain, headache, back pain, bone pain, increased cough, dyspnea, pharyngitis and peripheral edema. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc., at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Adjuvant Therapy Adverse reaction data for adjuvant therapy are base...

adverse reactions table

Table 1 – Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment, or within 14 days of the end of treatment in the ATAC trialThe combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up.Body system and adverse reactions by COSTARTCOSTART Coding Symbols for Thesaurus of Adverse Reaction Terms. preferred termA patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system.Anastrozole tablets 1 mg (NN=Number of patients receiving the treatment. = 3092)Tamoxifen 20 mg (N = 3094)Body as a wholeAsthenia575 (19)544 (18)Pain533 (17)485 (16)Back pain321 (10)309 (10)Headache314 (10)249 (8)Abdominal pain271 (9)276 (9)Infection285 (9)276 (9)Accidental injury311 (10)303 (10)Flu syndrome175 (6)195 (6)Chest pain200 (7)150 (5)Neoplasm162 (5)144 (5)Cyst138 (5)162 (5)CardiovascularVasodilatation1104 (36)1264 (41)Hypertension402 (13)349 (11)DigestiveNausea343 (11)335 (11)Constipation249 (8)252 (8)Diarrhea265 (9)216 (7)Dyspepsia206 (7)169 (6)Gastrointestinal disorder210 (7)158 (5)Hemic and lymphaticLymphedema304 (10)341 (11)Anemia113 (4)159 (5)Metabolic and nutritionalPeripheral edema311 (10)343 (11)Weight gain285 (9)274 (9)Hypercholesterolemia278 (9)108 (3.5)MusculoskeletalArthritis512 (17)445 (14)Arthralgia467 (15)344 (11)Osteoporosis325 (11)226 (7)Fracture315 (10)209 (7)Bone pain201 (7)185 (6)Arthrosis207 (7)156 (5)Joint Disorder184 (6)160 (5)Myalgia179 (6)160 (5)Nervous systemDepression413 (13)382 (12)Insomnia309 (10)281 (9)Dizziness236 (8)234 (8)Anxiety195 (6)180 (6)Paresthesia215 (7)145 (5)RespiratoryPharyngitis443 (14)422 (14)Cough increased261 (8)287 (9)Dyspnea234 (8)237 (8)Sinusitis184 (6)159 (5)Bronchitis167 (5)153 (5)Skin and appendagesRash333 (11)387 (13)Sweating145 (5)177 (6)Special SensesCataract Specified182 (6)213 (7)UrogenitalLeukorrhea86 (3)286 (9)Urinary tract infection244 (8)313 (10)Breast pain251 (8)169 (6)Breast Neoplasm164 (5)139 (5)Vulvovaginitis194 (6)150 (5)Vaginal HemorrhageVaginal Hemorrhage without further diagnosis.122 (4)180 (6)Vaginitis125 (4)158 (5)

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50090-2005AnastrozoleAnastrozoleA-S Medication SolutionsANDACurrent
60429-286AnastrozoleAnastrozoleGolden State Medical Supply, Inc.ANDACurrent
60429-286AnastrozoleAnastrozoleGolden State Medical Supply, Inc.ANDACurrent
60429-286AnastrozoleAnastrozoleGolden State Medical SupplyANDACurrent
60505-2985AnastrozoleAnastrozoleApotex Corp.ANDACurrent
60505-2985AnastrozoleAnastrozoleApotex Corp.ANDACurrent
71335-0023AnastrozoleAnastrozoleBryant Ranch PrepackANDACurrent